sales@debyesci.com
|
00852-3115 8545
Structure Search

Product

WE ONLY MAKE FINE PRODUCTS

DM4

Catalog_Number:

DS-028663

CAS:

796073-69-3

Formula:

C38H54ClN3O10S

Formula_Weight:

780.4

Purity:

99%
NOTICE: THE PRODUCT IS JUST ONLY FOR LAB RESEARCH, NOT FOR OTHER USE.
  • Unit

  • Price

  • Stock

  • 100mg

  • USD1000.0

  • 100mg

  • 500mg

  • USD3000.0

  • 500mg

  • 1g

  • USD5000.0

  • 1g

  • 5g

  • POA

  • 10g

InChI InChI=1S/C38H54ClN3O10S/c1-21-12-11-13-28(49-10)38(47)20-27(50-35(46)40-38)22(2)33-37(6,52-33)29(51-34(45)23(3)41(7)30(43)14-15-36(4,5)53)19-31(44)42(8)25-17-24(16-21)18-26(48-9)32(25)39/h11-13,17-18,22-23,27-29,33,47,53H,14-16,19-20H2,1-10H3,(H,40,46)/b1
InChiKey JFCFGYGEYRIEBE-YVLHJLIDSA-N

DM4 has anticancer properties of maytansinoids due to their ability to disrupt microtubule function. Maytansinoid DM4 can be use to make antibody drug conjugates such as Anetumab ravtansine (BAY 94-9343) and Indatuximab ravtansine (BT062). Maytansinoids inhibit tubulin polymerization and microtubule assembly and enhance microtubule destabilization, so there is potent suppression of microtubule dynamics resulting in a mitotic block and subsequent apoptotic cell death.

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.
Zhao XY, et al. Clin Cancer Drv gs. 2016 Oct;3(2):76-86. PMID: 27853672.

P-gp Activity Is a Critical Resistance Factor Against AVE9633 and DM4 Cytotoxicity in Leukaemia Cell Lines, but Not a Major Mechanism of Chemoresistance in Cells From Acute Myeloid Leukaemia P atl ents.
Ruoping Tang, et al. BMC Cancer. 2009 Jun 23;9:199. PMID: 19549303.


Call It